Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
23andme
ally bridge group
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
bio
biology
blackrock
bluebird bio
casdin capital
diabetic nephropathy
duchenne muscular dystrophy
dyne therapeutics
eventide asset management
facioscapulohumeral muscular dystrophy
focal segmental glomerulosclerosis
food and drug administration
gene therapy
genetic testing
goldfinch bio
health
irving investors
jay ghosh
joshua brumm
kaleido biosciences
medicine
muscular dystrophy
myotonic dystrophy type 1
new york blog main
rare disease drugs
What
diseases
3
×
drug
3
×
genetic
3
×
ipo
long
medicines
ability
accompanying
administration
ago
allowed
alzheimers
analysis
andme
andme’s
associated
bio
biotech
biotechs
bring
company
considering
consumers
data
develop
dyne
early
employing
expected
experimental
eyes
fda
finally
food
gave
genes
goldfinch
green
having
health
Language
unset
Current search:
genetic
×
drug
×
diseases
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@techcrunch.com
7 years ago
23andMe is finally allowed to tell you if you have the genes for Parkinsons